Hoag Health Center San Clemente
SAN CLEMENTE, Calif., July 14, 2025 /PRNewswire/ — Hoag has officially opened the doors to its newest facility, Hoag Health Center San Clemente, expanding access to world-class, personalized health care for South Orange County residents. As Hoag's 13th health center, the facility strengthens the health system's growing network of care and brings trusted services closer to home for South Orange County patients.
The 20,000-square-foot center offers convenient access to primary care, family medicine, internal medicine, urgent care, obstetrics and gynecology, radiology and advanced imaging, as well as specialties including neuroscience, spine, pain management and orthopedic services provided by Hoag Orthopedic Institute surgeons.
'We've built Hoag Health Center San Clemente with our community in mind by integrating cutting-edge technology, a multidisciplinary care model, and a patient-first design to deliver the most advanced care possible,' said Robert T. Braithwaite, Hoag President and Chief Executive Officer. 'This new center reflects our long-term commitment to South Orange County and reinforces Hoag's mission to provide personalized care and an exceptional experience for every patient.'
In addition to expanding Hoag's clinical footprint, the health center introduces innovative programs aimed at improving health and longevity.
The center is piloting the Hoag Health Lab, a destination for patients to take a proactive approach to their health. It offers baseline evaluations for key health pillars – nutrition, exercise, sleep and community – through nutritional/metabolic assessments, movement and strength benchmarking, and recovery education. An adjacent 3,000-square-foot outdoor patio will host wellness classes and activities.
The center is also home to Hoag Compass, Hoag's integrated preventive health program. Compass combines in-depth biomarker testing with digital tools, specialist consults and personalized action plans to help patients better understand their health risks and make sustainable lifestyle changes.
No matter the service or specialty, the care delivered at the center will reflect what patients have come to expect from Hoag: personalized attention, strong provider relationships, and seamless coordination between clinical teams. Whether visiting for a routine checkup or a specialty consultation, patients will benefit from a connected, collaborative model of care rooted in innovation, compassion and excellence.
Patients will receive this coordinated, personalized care in an environment designed with serenity and sophistication in mind. Hoag Health Center San Clemente features a spacious, open layout that blends natural light, clean architectural lines, and timeless materials. A sprawling, light-filled lobby creates a welcoming first impression with a spa-like aesthetic. Flexible seating and built-in amenities ensure the space supports an exceptional patient experience at every step.
Inspired by San Clemente's active, outdoor lifestyle, Hoag Health Center San Clemente was designed to support the way residents live, move and thrive. That includes partnerships with wellness-focused brands that align with the community's values of movement, performance and prevention.
'As a San Clemente resident myself, I'm proud to help bring this new level of care to our community,' Braithwaite added. 'This center is more than a building: It's an investment in the health and vitality of the families who live here.'
Hoag Health Center San Clemente is located at 993 Avenida Pico, San Clemente, CA 92673. To learn more or schedule an appointment, visit hoag.org/san-clemente.
Photographs of the center are available here.
ABOUT HOAGHoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 18 urgent care facilities, 13 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women's health, and orthopedics through Hoag's affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and five ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® with Distinction hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Global Influenza Market Surges Amid Diagnostic Innovation
'Rise in Influenza Cases Drives Demand for Rapid Diagnostics and Molecular Testing Solutions, Fueling Innovation and Growth Across the Global Influenza Market' BOSTON, July 15, 2025 /PRNewswire/ — According to the latest study from BCC Research, 'The Global Influenza Market' is expected to grow from $9.0 billion in 2024 to $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029. This report offers a well-rounded analysis of the global influenza market, covering both historical and current trends. It examines the disease burden, vaccine coverage, and market dynamics across the major regions of North America, Europe, and Asia-Pacific. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests). It also highlights leading products, clinical trials, new approvals, and emerging technologies. Additionally, the report profiles major companies and outlines their strategies, while providing growth forecasts and opportunities for each product segment in major regions. This report is particularly relevant today because public health systems and healthcare providers need to prepare for a potential rise in influenza cases. It helps forecast how many people could need to seek medical care, what quantity of drugs or vaccines will be needed, and which resources such as hospital beds or antivirals might be stretched. For pharmaceutical companies, the report is crucial for identifying areas with strong demand and adjusting their production or distribution strategies accordingly to ensure the timely and efficient delivery of flu vaccines and treatments. The factors driving the market's growth include: Faster Testing Technologies: New rapid tests and molecular tools help detect flu viruses quickly and accurately. This allows doctors to treat patients sooner and helps prevent the spread of the virus, boosting demand for diagnostics. Government Support: Governments are funding research and speeding up approvals for new flu treatments and tests. This support encourages innovation and helps bring new products to market faster. More Vaccine Awareness: People are more aware of the importance of flu shots, especially after recent global health events. Public campaigns and easier access to vaccines have led to higher vaccination rates. Request a sample copy of the global influenza market report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $8.4 billion Market size forecast $12.8 billion Growth rate CAGR of 7.2% for the forecast period of 2024-2029 Segments covered Vaccines, Therapeutics, Diagnostics, and Region Regions covered North America, Asia-Pacific, Europe, Rest of the World (includes South America, and the Middle East and Africa) Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, Australia, Market drivers • Development of rapid tests and molecular technologies. • Government support and funding for novel therapies and diagnosis. • Rising public awareness of the need for flu vaccines. Interesting facts: GSK Begins Early Flu Vaccine Distribution: Ahead of the 2024–2025 flu season, GSK plc has started shipping its trivalent influenza vaccines across the U.S. This rollout follows the FDA's approval of the lot release and licensing, ensuring timely availability at pharmacies and healthcare facilities. Sanofi's Dual Vaccine Candidates Fast-Tracked: In December 2024, the FDA granted Fast Track designation to two of Sanofi's combination vaccine candidates designed to protect individuals 50 and older from influenza and COVID-19. These candidates merge two already approved vaccines, each proven effective and well-tolerated in clinical trials. FluMist, the First Self-Administered Flu Vaccine Approved in the U.S.: In a groundbreaking move, the FDA approved FluMist in 2024 as the only self-administered influenza vaccine available in the U.S. Adults up to age 49 can now use this needle-free nasal spray on their own, while parents or caregivers can administer it to children 2 to 17. The approval was based on a comprehensive submission, including a usability study confirming that adults could safely administer the vaccine to themselves or others within the eligible age range. Emerging startups Ansun BioPharma Virolock Technologies Vaxart The report addresses the following questions: What is the projected size and growth rate of the market?–The global influenza market was valued at $8.4 billion in 2023 and is expected to reach $12.8 billion by the end of 2029. The market is expected to grow at a CAGR of 7.2% from 2024 to 2029. What factors are driving the growth of the market?– Factors that are driving the market's growth are the development of rapid tests and molecular technologies, government support and funding for novel therapies and diagnosis, and rising public awareness about flu vaccines. Which market segments are covered in the report?– The market size for influenza is categorized into three product segments: Vaccines, Therapeutics, and Diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. The diagnostics, market is divided into rapid tests and conventional lab tests. Which product segment will be dominant through 2029?– Vaccines will be the dominant market segment through 2029. Which region has the highest market share?–The North American market for influenza was valued at $4.2 billion in 2023 and is projected to reach $6.3 billion in 2029, at a CAGR of 7.3% during the forecast period. Market leaders include: ABBOTT ASTRAZENECA BECTON DICKINSON BIOCRYST PHARMACEUTICALS INC. CSL DAIICHI SANKYO CO. LTD. DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GSK PLC. HOLOGIC INC. QUIDELORTHO CORP. SANOFI SEKISUI DIAGNOSTICS THERMO FISHER SCIENTIFIC INC. VIATRIS INC. Related reports: Global Markets for Vaccine Technologies: This report provides an in-depth look at the human vaccine industry, focusing on key trends, market drivers and restraints, and the impact of new technologies and competition. It covers vaccine types, including pneumococcal, HPV, MMR, and influenza, but excludes animal vaccines. The study also examines R&D spending, product launches, and strategic moves like mergers, acquisitions and collaborations. It offers insights for stakeholders such as manufacturers, researchers, healthcare providers, and government agencies, with detailed regional analysis to support market expansion efforts. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo –
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Feel Good Foods Delivers Craveable, Gluten-Free Satisfaction With New Crispy Chicken Bites
NEW YORK, July 15, 2025 /PRNewswire/ — The rumors are true: Feel Good Foods®, the #1 Natural Brand in Frozen Snacks & Appetizers, has launched the ultimate crave-worthy snack: gluten-free Crispy Chicken Bites! 'These Crispy Chicken Bites deliver delicious flavor in every bite. It's elevated comfort food – you'd never believe they're gluten-free!' says Vanessa Phillips, founder of Feel Good Foods. Tender, crispy, and with 16 grams of protein per serving, these Feel Good Foods Crispy Chicken Bites are made to satisfy and fuel. Each 10oz pack contains white meat chicken bites fried to perfection in a crispy tempura batter and served with sweet chili dipping sauce. Made with real, simple ingredients and certified gluten-free, consumers can feel good about indulging in these chicken bites. Cooking in just minutes in the air fryer or oven, Feel Good Foods Crispy Chicken Bites are designed to deliver a deliciously satisfying experience that requires minimal time and effort. This new addition to the Feel Good Foods portfolio is poised to appeal to a broad audience of crispy chicken lovers, gluten-free or not. Feel Good Foods Crispy Chicken Bites joins an all-star lineup of delicious consumer favorites, including new Mini Pizza Bagels, Mozzarella Sticks, and Pancake Balls. About Feel Good Foods:Feel Good Foods is a company specializing in simple, delicious, certified gluten-free frozen snacks, appetizers, and breakfast. Founded by Vanessa Phillips, who was diagnosed with celiac disease, the company aims to recreate beloved comfort foods without gluten, ensuring that everyone, including gluten-free consumers, can enjoy their favorite dishes. Learn More by visiting and following Feel Good Foods on social media:Instagram: @feelgoodfoods Facebook: Feel Good FoodsTikTok: @feelgf Contact: mediarelations@
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Quest Diagnostics Introduces Testing for Oropouche Virus
Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J., July 15, 2025 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is increasingly found in South and Central America and the Caribbean. 'As one of the leading providers of laboratory testing, Quest plays an essential role in ensuring the U.S. is prepared to respond to potentially dangerous emerging diseases, such as Oropouche virus,' said Yuri Fesko, MD, Senior Vice President and Chief Medical Officer at Quest Diagnostics. 'By developing this test, we are prepared to act quickly to offer scalable testing to complement public health labs should this virus become a public health threat.' Oropouche virus is an emerging virus in the Americas that is spread to people by infected biting midges and some mosquito species. While the current threat to the public in North America remains low, Oropouche virus has been reported in parts of South America, Central America and the Caribbean, with the majority of infected individuals becoming symptomatic. Cases reported in the United States have been limited to travelers returning from countries with local transmission. Oropouche viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika and chikungunya. While most people recover on their own, Oropouche virus can also cause more severe neuroinvasive disease like meningitis and encephalitis. The test will be available with a prescription from a provider for clinical purposes at the end of the month. Quest's advanced laboratory in San Juan Capistrano, California, developed and will perform the test using polymerase chain reaction (PCR) technology, with serology testing to follow later this quarter. Reverse transcription PCR testing can identify the RNA of the virus during the early stages of infection to aid diagnosis. Serology testing, which identifies antibodies produced by the immune system in response to the virus, can help diagnose the virus in later stages of infection. In September 2024, Quest Diagnostics was awarded several contracts by the U.S. Centers for Disease Control and Prevention (CDC) to support testing and sustained laboratory readiness for emerging infectious diseases, including the development of diagnostics to aid the detection of Oropouche virus. The company also launched the first commercially available diagnostic test for Avian Influenza A H5 based on the funding. The contracts provide funding to enable the company to maintain testing readiness, such as for adequate supplies of certain equipment and chemical reagents used to perform the tests, on a sustained basis, should the U.S. need to quickly mobilize response to safeguard public health. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world.
